Serum_and_tissue_alpha-L-fucosidase_activity_in_the_pre-clinical_and_clinical_stages_of_hepatocellular_carcinoma._1._To_assess_the_value_of_serum_alpha-L-fucosidase_(EC_3.2.1.51)_as_a_marker_for_hepatocellular_carcinoma,_the_activity_was_measured_in_patients_with_hepatocellular_carcinoma_and_in_control_subjects._2._Mean_serum_alpha-L-fucosidase_activity_was_significantly_greater_in_35_patients_with_hepatocellular_carcinoma_(225_+/-_69_nkat/l)_than_in_35_patients_with_cirrhosis_and_20_normal_subjects_(134_+/-_30_and_93_+/-_28_nkat/l,_respectively)._The_overlap_between_hepatocellular_carcinoma_and_cirrhosis,_however,_was_such_as_to_severely_limit_any_value_of_the_enzyme_as_a_diagnostic_test._3._In_four_cirrhotic_patients_with_hepatocellular_carcinoma,_an_increased_enzyme_activity_was_detectable_in_samples_taken_up_to_66_months_before_the_tumours_were_diagnosed_clinically._4._The_serum_activity_of_alpha-L-fucosidase_fell_to_within_the_reference_range_after_liver_transplantation_for_hepatocellular_carcinoma_in_three_patients_and_in_one_of_these_a_subsequent_rise_was_associated_with_tumour_recurrence_which_was_diagnosed_at_8_months_after_the_rise_in_activity._Ineffective_cytotoxic_chemotherapy_was_also_associated_with_a_progressive_rise_in_serum_alpha-L-fucosidase_activity._5._alpha-L-fucosidase_activity_in_tumour_tissue_was_significantly_lower_than_that_seen_in_non-tumour_tissue_from_cirrhotic_patients._These_reductions_may_represent_increased_transport_from_the_tissue_and_may_partly_account_for_the_increased_serum_activity_found_in_some_patients_with_hepatocellular_carcinoma.